|Bid||21.44 x 1000|
|Ask||0.00 x 800|
|Day's Range||20.87 - 21.78|
|52 Week Range||17.27 - 38.01|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Annexon (ANNX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Annexon Inc (NASDAQ: ANNX) has commenced patient dosing in its Phase 2 ARCHER study evaluating ANX007 to treat Geographic Atrophy (GA). GA, also known as atrophic age-related macular degeneration (AMD) or dry AMD, can lead to blindness caused by damaged and dying retinal cells. The Phase 2 trial is designed to evaluate the efficacy and safety of ANX007. Monthly dosing schedules will be evaluated. ANX007 is a monoclonal antibody formulated for intravitreal administration. The drug candidate is designed to bind to C1q and inhibit activation of all downstream components of the classical complement cascade, including C3 and C5, but not to interfere with the normal function of C3 and C5. Price Action: ANNX shares gained 10.6% at $32.19 in market trading hours on the last check Monday. See more from BenzingaClick here for options trades from BenzingaOcular Therapeutix Shares Are Trading Higher As Company Starts Dosing In Mid-Stage Therapy Study For Dry Eye DiseaseFlexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.